Author

T. Dott

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1

Frequent Co-Authors

B. Terrier· 2 shared D. Duffy· 2 shared A. Baudry· 1 shared A. Llibre· 1 shared A.-S. Korganow· 1 shared B. Bader-Meunier· 1 shared B. Beitz· 1 shared B. Jagla· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. Terrier

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

High-dimensional spectral cytometry panels for whole blood immune phenotyping

T. Dott, S. Culina, R. Chemali, C. Ait Mansour, F. Dubois, B. Jagla, J. M. Doisne, L. Rogge, F. Huetz, F. Jönsson, P.-H. Commere, J. Di Santo, B. Terrier, L. Quintana-Murci, D. Duffy, , Milieu Interieur Consortium

The paper develops high-dimensional spectral flow cytometry panels for immune phenotyping in healthy donors and applies them to study immune variation in autoimmune diseases.

bioRxiv · Jul 17, 2023 · PreprintImmunology

Targeting the chemokine receptor CXCR4 with histamine analogue to reduce inflammation in juvenile arthritis: a proof of concept for COVID-19 therapeutic approach

N. Bekaddour, N. Smith, B. Beitz, A. Llibre, T. Dott, A. Baudry, A.-S. Korganow, S. Nisole, R. Mouy, S. Breton, B. Bader-Meunier, D. Duffy, B. Terrier, B. Schneider, P. Quartier, , J.-P. Herbeuval

This study shows that targeting CXCR4 with clobenpropit reduces inflammation in juvenile arthritis and COVID-19 by lowering cytokine levels and immune cell activity.

bioRxiv · Oct 24, 2021 · PreprintImmunology